Skip to main content

Monoclonal Antibodies In India | 2023

monoclonal antibodies india
Monoclonal antibodies are laboratory-produced proteins that are designed to mimic the immune system's ability to fight off infections and diseases. They are made by cloning a single immune cell, resulting in an identical population of cells that all produce the same antibody. Monoclonal antibodies are used to treat a variety of conditions, including cancer, autoimmune disorders, and certain infections.

Monoclonal Antibodies In India are increasingly being used to treat a variety of medical conditions. One of the main advantages of monoclonal antibodies is their ability to target specific cells or proteins in the body, which makes them more selective and effective than traditional treatments. For example, they can be used to target and destroy cancer cells while leaving healthy cells unharmed.

There are several monoclonal antibodies that have been approved for use in India, including rituximab, trastuzumab, and adalimumab. These drugs are used to treat conditions such as leukemia, breast cancer, and rheumatoid arthritis, respectively. For more detail information about Monoclonal Antibodies India, visit Genextgenomics.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Impact of CDR Length on Antibody Functionality

  Image by freepik Antibodies rely on their complementarity-determining regions (CDRs) to recognize and bind antigens with high specificity. Among these regions, CDR3-particularly in the heavy chain (CDR-H3)-exhibits remarkable length diversity, directly influencing antigen recognition, structural stability, and therapeutic efficacy. Understanding how CDR length shapes antibody functionality is critical for advancing biologics, diagnostics, and immunotherapy . The Role of CDR-H3 in Antibody Diversity CDR-H3 is the most variable region in antibodies, formed by the recombination of V, D, and J gene segments. Its length ranges widely: Human antibodies: Typically, 11–20 amino acids (median 14), forming a near-normal distribution. Bovine antibodies: Feature ultra-long CDR-H3s (>50 residues) with unique "stalk-knob" structures for deep antigen binding. This length diversity expands the antibody repertoire, enabling recognition of structurally diverse antigens, from small molecul...
Post a Comment
Read more

TB: Time Is Running Out!

  Tuberculosis, caused by Mycobacterium tuberculosis , is a severe disease that mainly affects the lungs. TB remains the deadliest killer disease despite the current epidemic of COVID.  Like COVID, Tuberculosis bacteria can spread from person to person through sneezing and coughing And post COVID, and the Corona Virus has also posed a risk to people with TB. TB is a potentially fatal disease and has many causes, yet it is preventable and has a wide range of treatments in the market. When the TB affects the lungs, the disease results in being more contagious, with the person usually getting sick and close contact with them can make others affected too. Hence, it also brings isolation and social stigma to the patient suffering from TB.  It is mainly considered the disease of the poor as it is prevalent in a more crowded area with fewer resources. TB remains with us in a different form. TB Infection (Latent TB):  An individual with TB bacteria in the body who shows no s...
Post a Comment
Read more

Mastering Hybridoma Technology Steps: Uncover the Process at GenextGenomics

Dive into the nuanced process of Hybridoma Technology Steps on GenextGenomics. Our detailed guide elucidates the fusion, screening, and culturing stages crucial in producing monoclonal antibodies. Empower your research and development endeavors with insights into this groundbreaking biotech methodology. Explore GenextGenomics for a comprehensive understanding. Ready to leverage the potential of Hybridoma Technology? Join us to revolutionize your biotech journey today! Explore the Potential of Hybridoma Technology with GenextGenomics!
Post a Comment
Read more